Sirnaomics Ltd. (HK:2257)
:2257
Want to see HK:2257 full AI Analyst Report?
Top Page
Sirnaomics Ltd.
(2257)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$5.50
▼(-31.25% Downside)
Action:Reiterated
Date:05/01/26
The score is primarily constrained by weak financial performance—zero/volatile revenue, continued losses and cash burn, and especially negative shareholder equity that elevates funding risk. Technicals add pressure as the stock trades below all major moving averages, despite oversold signals. Valuation contributes limited support due to negative earnings and no stated dividend yield.
Positive Factors
Narrowing net loss
The material narrowing of net loss in 2025 versus prior years suggests improving cost structure or program discipline. Sustained reduction in losses over several quarters can extend runway and reduce near-term financing pressure, supporting continued R&D execution.
Negative Factors
Zero/volatile revenue
Revenue absence and volatility mean the business is not generating predictable commercial cash flow. This undermines self-sufficiency, forces reliance on external funding for R&D, increases dilution risk, and limits ability to invest steadily in programs long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing net loss
The material narrowing of net loss in 2025 versus prior years suggests improving cost structure or program discipline. Sustained reduction in losses over several quarters can extend runway and reduce near-term financing pressure, supporting continued R&D execution.
Read all positive factors
Sirnaomics Ltd. (2257) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$639.68M
Dividend YieldN/A
Average Volume (3M)442.62K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth-100.00%
EPS Growth77.06%
CountryHK
Employees69
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding109,721,535
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Sirnaomics Ltd. Business Overview & Revenue Model
Company Description
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates i...
How the Company Makes Money
null...
Sirnaomics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 1.78M | 397.00K | 705.00K | 0.00 |
| Gross Profit | -1.84M | 1.20M | 397.00K | 705.00K | -12.67M |
| EBITDA | -13.53M | -31.12M | -72.36M | -89.02M | -1.66B |
| Net Income | -14.42M | -51.38M | -78.69M | -88.30M | -1.66B |
Balance Sheet | |||||
| Total Assets | 20.60M | 28.33M | 75.79M | 163.93M | 240.65M |
| Cash, Cash Equivalents and Short-Term Investments | 13.52M | 11.77M | 43.93M | 105.23M | 211.99M |
| Total Debt | 9.31M | 8.06M | 8.85M | 10.76M | 7.04M |
| Total Liabilities | 45.09M | 44.33M | 51.33M | 52.37M | 30.36M |
| Stockholders Equity | -9.91M | -1.68M | 40.20M | 122.01M | 211.62M |
Cash Flow | |||||
| Free Cash Flow | -9.25M | -19.84M | -72.03M | -107.54M | -62.85M |
| Operating Cash Flow | -9.20M | -19.73M | -70.29M | -88.71M | -56.97M |
| Investing Cash Flow | 23.00K | 2.14M | -5.35M | -32.61M | -6.04M |
| Financing Cash Flow | 10.95M | 5.82M | -5.61M | 15.89M | 170.96M |
Sirnaomics Ltd. Technical Analysis
Negative
8.00
Price Trends
6.47
Negative
7.28
Negative
9.13
Negative
Market Momentum
-0.25
Positive
38.84
Neutral
42.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Negative. The current price of 8 is above the 20-day moving average (MA) of 6.32, above the 50-day MA of 6.47, and below the 200-day MA of 9.13, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 38.84 is Neutral, neither overbought nor oversold. The STOCH value of 42.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2257.
Sirnaomics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$3.38B | -16.22 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$12.15B | -15.04 | -64.19% | ― | -33.37% | -344.90% | |
49 Neutral | HK$3.32B | -6.73 | 11.40% | ― | -90.96% | 77.66% | |
44 Neutral | HK$639.68M | -2.18 | 191.92% | ― | -100.00% | 77.06% | |
44 Neutral | HK$1.82B | -7.60 | -27.70% | ― | -100.00% | 50.29% | |
44 Neutral | HK$863.76M | ― | -27.44% | ― | -33.80% | 31.52% |
* Healthcare Sector Average
HK:2257
Sirnaomics Ltd.
5.83
2.80
92.41%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.37
2.54
138.80%
HK:2197
Clover Biopharmaceuticals Ltd.
2.56
2.32
966.67%
HK:2616
CStone Pharmaceuticals
7.70
4.04
110.38%
HK:3681
SinoMab Bioscience Ltd.
1.32
0.04
3.13%
HK:6628
Transcenta Holding Limited
1.94
0.33
20.50%
Sirnaomics Ltd. Corporate Events
Sirnaomics Moves to Replace 2022 Equity Plan With New 2026 Share Option Scheme
Apr 22, 2026
Sirnaomics Ltd. plans to terminate its share option scheme adopted in 2022 and introduce a new 2026 Share Option Scheme aligned with the latest Chapter 17 requirements of the Hong Kong listing rules. Options already granted under the existing sche...
Sirnaomics Unveils New Corporate Logo Without Affecting Shareholder Rights
Apr 10, 2026
Sirnaomics Ltd. has adopted a new corporate logo with immediate effect, which will appear on future corporate documents and be displayed on the company’s website as part of an updated brand identity. The move signals a refreshed corporate im...
Sirnaomics Moves to Modernize Governance With Hybrid Meeting and E-Voting Rules
Apr 10, 2026
Sirnaomics Ltd. plans to amend its existing memorandum and articles of association to align with recent changes to Hong Kong Listing Rules on hybrid general meetings and electronic voting, along with other housekeeping updates. The company will se...
Sirnaomics Chairman Boosts Stake, Signaling Confidence in Growth Prospects
Mar 30, 2026
Sirnaomics Ltd., a Hong Kong-listed biopharmaceutical company specializing in RNAi-based therapeutics, reported a change in its ownership structure following a share purchase by its chairman. The group continues to position itself as an innovator ...
Sirnaomics Advances RNAi Pipeline With Key 2025 Clinical Milestones
Mar 27, 2026
Sirnaomics reported its audited 2025 annual results, highlighting resilience amid a difficult global economy and continued advancement of its RNAi therapeutic pipeline. The company emphasized strategic restructuring and operational efficiency as k...
Sirnaomics Moves to Replace 2022 RSU Plan With New 2026 Scheme
Mar 24, 2026
Sirnaomics plans to terminate its existing 2022 Restricted Share Unit scheme and replace it with a new 2026 RSU scheme, aligning its equity incentive structure with updated Chapter 17 requirements of the Hong Kong Listing Rules. The 2022 scheme wi...
Sirnaomics Sets Board Meeting to Approve 2025 Annual Results
Mar 13, 2026
Sirnaomics Ltd. has scheduled a board meeting for March 27, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The announcement signals that the company is preparing to release ...
Sirnaomics Partially Completes Share Subscription and Raises HK$53.1 Million
Mar 8, 2026
Sirnaomics Ltd. has partially completed a previously announced share subscription, issuing 2,500,000 new shares to Subscriber A at HK$12.00 each, while mutually agreeing to terminate the subscription for the remaining 9,068,280 shares without any ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.